Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | GCK | P35557 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426961 | 0.89 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL862870 | 0.89 | MEN1 (0.93) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL27681012 | 0.88 | MEN1 (0.74) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL10200059 | 0.88 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| Hydrochloric Acid SCHEMBL6841086 | 0.87 | MEN1 (0.96) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL3132629 | 0.85 | LMNA (0.62) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL4910012 | 0.85 | MEN1 (0.62) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL3271153 | 0.85 | CYP4F2 (0.61) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL7358147 | 0.84 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 | |
| SCHEMBL2570286 | 0.84 | MEN1 (0.84) | MEN1KMT2ASMN1; SMN2TSHRNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | MEN1 2493/4885KMT2A 2015/4885SMN1; SMN2 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.